CN109073638B - 抑制aimp2-dx2和hsp70结合的抗癌剂的筛选方法 - Google Patents

抑制aimp2-dx2和hsp70结合的抗癌剂的筛选方法 Download PDF

Info

Publication number
CN109073638B
CN109073638B CN201780027761.8A CN201780027761A CN109073638B CN 109073638 B CN109073638 B CN 109073638B CN 201780027761 A CN201780027761 A CN 201780027761A CN 109073638 B CN109073638 B CN 109073638B
Authority
CN
China
Prior art keywords
aimp2
hsp70
cancer
binding
anticancer agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780027761.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN109073638A (zh
Inventor
金圣勋
金旲圭
任世美
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical Life Fusion Research Group
Original Assignee
Medical Life Fusion Research Group
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medical Life Fusion Research Group filed Critical Medical Life Fusion Research Group
Publication of CN109073638A publication Critical patent/CN109073638A/zh
Application granted granted Critical
Publication of CN109073638B publication Critical patent/CN109073638B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN201780027761.8A 2016-03-07 2017-03-07 抑制aimp2-dx2和hsp70结合的抗癌剂的筛选方法 Active CN109073638B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2016-0027077 2016-03-07
KR1020160027077A KR102297505B1 (ko) 2016-03-07 2016-03-07 Aimp2-dx2와 hsp70의 결합을 저해하는 항암제 스크리닝 방법
PCT/KR2017/002442 WO2017155277A1 (ko) 2016-03-07 2017-03-07 Aimp2-dx2와 hsp70의 결합을 저해하는 항암제 스크리닝 방법

Publications (2)

Publication Number Publication Date
CN109073638A CN109073638A (zh) 2018-12-21
CN109073638B true CN109073638B (zh) 2022-04-26

Family

ID=59790548

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780027761.8A Active CN109073638B (zh) 2016-03-07 2017-03-07 抑制aimp2-dx2和hsp70结合的抗癌剂的筛选方法

Country Status (6)

Country Link
US (1) US11442057B2 (enExample)
EP (1) EP3418739B1 (enExample)
JP (1) JP6914269B2 (enExample)
KR (1) KR102297505B1 (enExample)
CN (1) CN109073638B (enExample)
WO (1) WO2017155277A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101831435B1 (ko) * 2016-03-10 2018-02-22 재단법인 의약바이오컨버젼스연구단 Aimp2-dx2 단백질에 특이적으로 결합하는 항체
US11758948B2 (en) 2018-01-29 2023-09-19 Altria Client Services Llc Lighting unit for aerosol-generating systems
JP7376484B2 (ja) 2018-01-29 2023-11-08 フィリップ・モーリス・プロダクツ・ソシエテ・アノニム エアロゾル発生システム用照明ユニット
JP7491510B2 (ja) 2018-04-26 2024-05-28 メディシナル バイオコンバージェンス リサーチ センター ｍＴＯＲ阻害剤としての新規化合物及びその用途
CA3213677A1 (en) * 2021-03-30 2022-10-06 Samir Hanash Citrullinated proteins as biomarkers and therapy targets for cancer
CN115786504B (zh) * 2022-08-31 2023-09-19 中国人民解放军总医院京南医疗区 Hspa4抑制剂在治疗黑素瘤中的应用

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1814909A1 (en) * 2004-11-24 2007-08-08 Seoul National University Industry Foundation Use of aimp2dx2 for the diagnosis and treatment of cancer
CN101087804A (zh) * 2004-11-24 2007-12-12 首尔大学工业基地 用于诊断和治疗癌症的aimp2dx2的用途
KR20090048382A (ko) * 2007-11-09 2009-05-13 재단법인서울대학교산학협력재단 Ａｉｍｐ2-ｄｘ2의 억제제를 유효성분으로 포함하는 염증성질환 예방 및 치료용 조성물
CN102985103A (zh) * 2010-05-04 2013-03-20 Atyr医药公司 与p38多-tRNA合成酶复合物相关的治疗、诊断和抗体组合物的创新发现
KR20130118671A (ko) * 2012-04-20 2013-10-30 단국대학교 산학협력단 Ａｉｍｐ２ 유전자의 스플라이싱 변이체 특이적인 트랜스-스플라이싱 활성을 갖는 핵산 분자 및 이를 이용한 폐암 치료용 약학 조성물 및 폐암 진단용 조성물
KR20140060184A (ko) * 2012-11-09 2014-05-19 주식회사 대웅 리보자임과 shRNA를 함유하는 아데노바이러스 및 이를 포함하는 암 치료용 조성물
WO2014142619A1 (ko) * 2013-03-14 2014-09-18 부산대학교산학협력단 Aimp2-dx2와 pl4/arf의 상호작용을 이용한 암 치료제의 스크리닝 방법
WO2014196784A1 (ko) * 2013-06-05 2014-12-11 재단법인 의약바이오컨버견스연구단 신규한 말레인산 유도체 및 이의 제조방법 및 이를 포함하는 항암용 조성물
CN104379565A (zh) * 2012-04-20 2015-02-25 医药生命融合研究团 新型氨基吡啶衍生物的癌预防或治疗用途
KR20150104719A (ko) * 2014-03-06 2015-09-16 한국과학기술원 Aimp2의 엑손2 결손체 돌연변이 검출용 분자신호기 및 이를 이용한 aimp2 돌연변이의 검출방법
WO2016003158A2 (ko) * 2014-06-30 2016-01-07 부산대학교 산학협력단 DX2 단백질과 p14/ARF 단백질 간의 결합을 억제하는 신규 화합물 및 상기 화합물을 유효성분으로 함유하는 암질환 치료 또는 예방용 약학조성물

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8039218B2 (en) * 2002-11-14 2011-10-18 John Wayne Cancer Institute Detection of cancer cells in body fluids
US8003780B2 (en) 2004-11-24 2011-08-23 Neomics Co., Ltd. AIMP2-DX2 gene and SiRNA targeting AIMP2-DX2
EP1872124A4 (en) * 2005-04-19 2008-06-11 Prediction Sciences Llc DIAGNOSTIC MARKERS FOR THE TREATMENT AND EVOLUTION OF BREAST CANCER AND METHODS OF USE
WO2007011856A2 (en) * 2005-07-15 2007-01-25 The Trustees Of Columbia University In The City Of New York Compositions and methods for differential diagnosis of chronic lymphocytic leukemia
KR20070113926A (ko) * 2006-05-26 2007-11-29 재단법인서울대학교산학협력재단 암의 진단과 치료를 위한 ａｉｍｐ2ｄｘ2의 용도
WO2009023846A2 (en) * 2007-08-15 2009-02-19 The Research Foundation Of State University Of New York Methods for heat shock protein dependent cancer treatment
WO2011035433A1 (en) * 2009-09-23 2011-03-31 University Health Network Selected strains on serum-free growth media for proteomics analysis of lung cancer biomarkers
WO2013006076A1 (en) * 2011-07-04 2013-01-10 New York University The use of intranasally administered hsp70 protein to treat neurodegenerative diseases
KR20130016041A (ko) * 2011-08-04 2013-02-14 재단법인 의약바이오컨버젼스연구단 신규한 아닐린 유도체 및 이의 용도
KR101514320B1 (ko) * 2013-06-14 2015-04-22 재단법인 의약바이오컨버젼스연구단 신규한 암 예방 또는 치료용 약학적 조성물

Patent Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1814909A1 (en) * 2004-11-24 2007-08-08 Seoul National University Industry Foundation Use of aimp2dx2 for the diagnosis and treatment of cancer
CN101087804A (zh) * 2004-11-24 2007-12-12 首尔大学工业基地 用于诊断和治疗癌症的aimp2dx2的用途
KR20090048382A (ko) * 2007-11-09 2009-05-13 재단법인서울대학교산학협력재단 Ａｉｍｐ2-ｄｘ2의 억제제를 유효성분으로 포함하는 염증성질환 예방 및 치료용 조성물
CN102985103A (zh) * 2010-05-04 2013-03-20 Atyr医药公司 与p38多-tRNA合成酶复合物相关的治疗、诊断和抗体组合物的创新发现
KR20130118671A (ko) * 2012-04-20 2013-10-30 단국대학교 산학협력단 Ａｉｍｐ２ 유전자의 스플라이싱 변이체 특이적인 트랜스-스플라이싱 활성을 갖는 핵산 분자 및 이를 이용한 폐암 치료용 약학 조성물 및 폐암 진단용 조성물
CN104379565A (zh) * 2012-04-20 2015-02-25 医药生命融合研究团 新型氨基吡啶衍生物的癌预防或治疗用途
KR20140060184A (ko) * 2012-11-09 2014-05-19 주식회사 대웅 리보자임과 shRNA를 함유하는 아데노바이러스 및 이를 포함하는 암 치료용 조성물
WO2014142619A1 (ko) * 2013-03-14 2014-09-18 부산대학교산학협력단 Aimp2-dx2와 pl4/arf의 상호작용을 이용한 암 치료제의 스크리닝 방법
KR101577315B1 (ko) * 2013-03-14 2015-12-15 부산대학교 산학협력단 AIMP2-DX2와 p14/ARF의 상호작용을 이용한 암 치료제의 스크리닝 방법
WO2014196784A1 (ko) * 2013-06-05 2014-12-11 재단법인 의약바이오컨버견스연구단 신규한 말레인산 유도체 및 이의 제조방법 및 이를 포함하는 항암용 조성물
KR20150104719A (ko) * 2014-03-06 2015-09-16 한국과학기술원 Aimp2의 엑손2 결손체 돌연변이 검출용 분자신호기 및 이를 이용한 aimp2 돌연변이의 검출방법
WO2016003158A2 (ko) * 2014-06-30 2016-01-07 부산대학교 산학협력단 DX2 단백질과 p14/ARF 단백질 간의 결합을 억제하는 신규 화합물 및 상기 화합물을 유효성분으로 함유하는 암질환 치료 또는 예방용 약학조성물

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Lentiviral Vector-Mediated shRNA against AIMP2-DX2 Suppresses Lung Cancer Cell Growth through Blocking Glucose Uptake;Seung-Hee Chang,et al.;《Mol Cells》;20120630;第33卷(第6期);全文 *

Also Published As

Publication number Publication date
WO2017155277A1 (ko) 2017-09-14
EP3418739A4 (en) 2019-03-06
CN109073638A (zh) 2018-12-21
KR102297505B1 (ko) 2021-09-01
WO2017155277A8 (ko) 2018-11-08
EP3418739B1 (en) 2021-05-12
JP2019512693A (ja) 2019-05-16
US11442057B2 (en) 2022-09-13
US20190033295A1 (en) 2019-01-31
JP6914269B2 (ja) 2021-08-04
EP3418739A1 (en) 2018-12-26
KR20170104263A (ko) 2017-09-15

Similar Documents

Publication Publication Date Title
CN109073638B (zh) 抑制aimp2-dx2和hsp70结合的抗癌剂的筛选方法
Hu et al. Antibiotic drug tigecycline inhibits melanoma progression and metastasis in a p21CIP1/Waf1-dependent manner
KR102344598B1 (ko) 간암의 예방 또는 치료용 조성물
PT2352508E (pt) Péptidos do domínio citoplasmático muc1 como inibidores de cancro
US20180312539A1 (en) Methods for preparing high throughput peptidomimetics, orally bioavailable drugs and compositions containing same
Khan et al. Identification of novel CD44v6-binding peptides that block CD44v6 and deliver a pro-apoptotic peptide to tumors to inhibit tumor growth and metastasis in mice
KR20140113543A (ko) AIMP2-DX2와 p14/ARF의 상호작용을 이용한 암 치료제의 스크리닝 방법
EP2857392A1 (en) Small compound targeting at tacc3
KR101367832B1 (ko) 종양 억제 타겟으로서 Ｈａｄｅｓ의 용도
Cho et al. Design of a PKCδ-specific small peptide as a theragnostic agent for glioblastoma
KR101771070B1 (ko) Mrs와 cdk4의 결합을 저해하는 항암제 스크리닝 방법
US9572855B2 (en) Combination anti-estrogen receptor cancer therapy using MUC1 peptides and chemotherapeutics
US9581598B2 (en) Diagnosis and treatment of brain tumor
Ludwig et al. The tumor suppressor, p190RhoGAP, differentially initiates apoptosis and confers docetaxel sensitivity to breast cancer cells
KR102290511B1 (ko) AIMP2-DX2와 K-Ras의 결합을 저해하는 항암제 스크리닝 방법
KR102658844B1 (ko) 펩티드 유도체 및 약학적 조성물
Li et al. Molecular mechanism of a novel CD59‐binding peptide sp22 induced tumor cells apoptosis
KR20210074253A (ko) Tsp1을 유효성분으로 포함하는 간암의 예방 또는 치료용 조성물
KR20200042389A (ko) Fgf2 또는 api5 유래 펩타이드 및 그의 용도
US20130345145A1 (en) Atip3 and biologically active fragments thereof for use in the treatment of cancer
KR100880850B1 (ko) 고형암 세포에서 사이클로필린 ａ의 발현을 억제하는물질을 포함하는 시스플라틴에 대한 내성 억제용 약제학적조성물 및 그를 이용하여 고형암의 시스플라틴에 대한내성을 억제하는 방법
EP2922862B1 (en) Complex-formation-modulating agents and uses therefor
AU2011260745B2 (en) Cancer therapy method
WO2006070804A1 (ja) テロメレース活性阻害方法および阻害剤
Han et al. Interaction of integrin linked kinase (ILK) and MCM7 mediating integrin α7 induced cell growth suppression

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant